Bill > S705

This bill, the Innovation in Pediatric Drugs Act of 2025, introduces several key changes to improve pediatric drug research and development. The bill modifies the Federal Food, Drug, and Cosmetic Act to enhance accountability for pediatric study requirements, providing a more structured approach to drug manufacturers' compliance. It establishes a new process where the FDA must issue a noncompliance letter and give drug companies a 45-day period to respond before taking enforcement action, and clarifies that enforcement actions will only be taken if a company demonstrates a lack of due diligence. The bill also requires the FDA to report on penalties and settlements related to pediatric study requirements and authorizes the National Institutes of Health to allocate up to 1% of their pediatric research funding for specific research initiatives. A significant provision addresses orphan drugs (medications for rare diseases), modifying how pediatric study requirements apply to these drugs by allowing waivers when studies are impractical or unlikely to provide meaningful therapeutic benefits. Additionally, the bill mandates a Government Accountability Office (GAO) study to assess the impact of these changes on rare disease drug development, requiring input from drug companies, patient groups, and medical associations. The overall goal is to improve pediatric drug research while providing more flexibility and clarity for pharmaceutical developers.

Health and Social Services

https://www.congress.gov/bill/119th-congress/senate-bill/705/all-info